Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Noble Corporation plc (NE) vs ResMed Inc. (RMD) Price & Performance

Noble Corporation plcTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Noble Corporation plc vs ResMed Inc. — how do they compare? Noble Corporation plc trades at $44.13 (market cap $7.10B), while ResMed Inc. trades at $225.37 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 4.6× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.5%). Which is the better fit depends on your goals.

NERMD
Market Cap
$7.10B$32.61B
Sector
TechnologyHealth
52-Week High
$54.37$293.73
52-Week Low
$26.61$182.82
Enterprise Value
$8.53B$31.97B
Dividend Yield
4.5%1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Noble Corporation plc

Noble Corporation (NE) trades at $44.48, up 2.14% today, with a bullish technical signal driven by moving averages. The stock shows mixed earnings performance, with a Q1 2026 beat but a Q2 2026 miss, while revenue and net income have declined year-over-year. Recent news highlights multiple law firm investigations into the company, adding uncertainty. The consensus price target is $46.00, slightly above the current price, with analysts divided between Buy (31%) and Hold (43%) ratings.

The outlook is cautious due to earnings volatility and legal scrutiny, though positive cash flow and a solid backlog of $6.8 billion provide some stability. Key risks include operational suspensions and investor litigation, while potential upside hinges on execution improvements and contract wins. The stock's valuation appears stretched with a P/E of 47.32, demanding strong future growth to justify current levels.

ResMed Inc.

ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.

The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.

Returns comparison

Trailing returns across standard periods

About Noble Corporation plc

Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.

Read more on NE

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD